Kevin C. Conlon, M.D.

Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.
1) immunotherapy, 2) IL-15
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10 - Magnuson Clinical Center, Room 3B38
Bethesda, MD 20892
Ph: 240-760-6087
Fax: 301-480-4442
conlonkc@mail.nih.gov
-
Avelumab (Bavencio) with IL-15 in subjects with clear-cell renal carcinoma
Open - RecruitingNCI Protocol ID NCI-20-C-0007Investigator Kevin C. Conlon, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Smoldering and Chronic Adult T-cell Leukemia (ATL)
Open - RecruitingNCI Protocol ID NCI-13-C-0006Investigator Kevin C. Conlon, M.D.Share this trial: Referral ContactsContact Name Phone Number Medical Oncology Referral Office 301-451-1228 Medical Oncology Referral Office 866-611-6310
Selected Publications
- J. Immunother.. 35: 629-40, 2012. [ Journal Article ]
- Blood. 120: 1816-9, 2012. [ Journal Article ]
- Blood. 121: 2029-37, 2013. [ Journal Article ]
- Blood. 121: 476-84, 2013. [ Journal Article ]
Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.
Name | Position |
---|---|
Jennifer Hsu R.N. | Research Nurse |
Nancy Beltran | Patient Care Coordinator (Contr.) |
Bonita Bryant | Medical Technologist |
Erin Corcoran | Data Manager (Contr.) |
Cathryn Lee | Clinical Collaborator |
Arlethia Spencer | Secretary |